CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Merck Sharp & Dohme Corp. vs. Genentech, Inc. et al.

πŸ“‘ 5G SEP β€’ ETSI Declared

Explore the PTAB proceeding IPR2016-01373 filed by Merck Sharp & Dohme Corp. on 2016-07-07. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2016-01373

Filing Date

2016-07-07

Accorded Filing Date

2016-07-07

Institution Decision Date

2017-01-03

Last Modified Date

β€”

Proceeding Type

IPR

Termination Date

β€”

Trial Status

Institution Denied

Parties & Counsel

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 07205419
Respondent Patent Number 6331415
Legal Expiration Date
β€” Term Verification Pending
Injunction Viability (35 U.S.C. Β§ 283) Active Threat
Respondent Inventor SHMUEL CABILLY
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

0 Total

Proceeding Status

Institution Denied

Administrative Patent Judges (APJ Panel)

Panel assignment tracked upon institution decision entry

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 9 proceedings
πŸ›οΈ
USPTO PTAB Trials 5 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Parallel Proceedings Across Jurisdictions (14 found):
PTAB: 5 U.S. Courts: 9
USPTO PTAB Trial 2016-10-11
IPR2017-00047

Merck Sharp & Dohme Corp. v. Genentech, Inc. et al.

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2016-03-03
IPR2016-00710

Mylan Pharmaceuticals Inc. et al. v. Genentech, Inc. et al.

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2016-01-15
IPR2016-00460

Genzyme Corporation et al. v. GENENTECH, INC. et al.

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2015-12-30
IPR2016-00383

GENZYME CORPORATION et al. v. Genentech Inc. et al.

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2015-07-27
IPR2015-01624

Sanofi-Aventis U.S. LLC et al. v. Genentech, Inc. et al.

Asserted Patent
Status: Terminated-Settled
U.S. District Court 2019-04-05
1:19-cv-00638

Genentech, Inc. v. Pfizer Inc.

Asserted Patent
Status: DED
U.S. District Court 2019-03-29
1:19-cv-00602

Genentech, Inc. v. Immunex Rhode Island Corp.

Asserted Patent
Status: DED
U.S. District Court 2018-09-04
1:18-cv-01363

Genentech, Inc. v. Samsung Bioepis Co., Ltd.

Asserted Patent
Status: DED
U.S. District Court 2018-07-11
1:18-cv-11553

GENENTECH, INC. v. CELLTRION, INC.

Asserted Patent
Status: NJD
U.S. District Court 2018-01-12
1:18-cv-00095

Genentech, Inc. v. Celltrion, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-10-18
1:17-cv-01471

Genentech, Inc. v. Amgen, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-10-06
1:17-cv-01407

Genentech, Inc. v. Amgen Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-10-01
2:13-cv-07248

Eli Lilly and Company v. Genentech, Inc.

Asserted Patent
Status: CACD
U.S. District Court 2010-04-15
2:10-cv-02764

Glaxo Group Limited v. Genentech, Inc.

Asserted Patent
Status: CACD
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP β€’ ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 4G / 5G LTE Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Sharp

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

βœ“ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
βœ“ Right to demand global FRAND portfolio determination.
βœ“ Non-discrimination defense: check licensing terms offered to competing implementers.

Proceeding Documents

126
17

Trial Instituted Document Paper

2017-01-03 FILING PARTY: BOARD
15

ORDER Petitioner's Motion for Pro Hac Vice Admission of Katherine A. Helm Paper

2016-12-13 FILING PARTY: BOARD
16

ORDER Patent Owner's Motions for Pro Hac Vice Admission of Ms. Durie and Mssrs. Gunther, Lipner, and Gindler Paper

2016-12-13 FILING PARTY: BOARD
14

Petitioner's Updated Mandatory Notices Paper

2016-11-01 FILING PARTY: PETITIONER
2033

T. Maniatis, et al., Molecular Cloning: A Laboratory Manual 11-14 (1982) Exhibits

2016-10-17 FILING PARTY: PATENT OWN

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc